Request for Proposals: Pfizer Quality Improvement Multiple Myeloma Care Program (Germany)

Pfizer is offering a competitive grant program aimed at enhancing the quality of care for Multiple Myeloma patients in Germany. This initiative seeks to integrate BCMA-targeting bispecific antibody therapy into standard clinical practice, improving health outcomes and quality of life for patients. The application deadline is 14 January 2027. This grant aims to support independent quality improvement initiatives that enhance the delivery and standardization of care for Multiple Myeloma patients undergoing bispecific antibody therapy. The program focuses on transitioning this therapy from specialized centers to routine clinical practice, optimizing patient management pathways, and improving care coordination. Projects should address needs and gaps in the care of MM patients, focusing on areas such as: This initiative plays a critical role in improving healthcare delivery for Multiple Myeloma patients in Germany by facilitating the broader implementation of innovative therapies. It supports healthcare providers in optimizing patient management and enhancing outcomes through structured care pathways and resource utilization. What is the maximum grant amount available? Up to €100,000 per project. Who can apply for this grant? Organizations based in Germany, including professional schools, healthcare institutions, and government agencies. What types of projects are supported? Projects focusing on clinical process optimization, safety management, and caregiver empowerment for Multiple Myeloma patients. When is the application deadline? 14 January 2027. Where can I find more information about the application process? Visit the Pfizer Requester Portal for more details. Interested organizations should review the official guidelines and prepare their applications by the specified deadline. For further details, consult the Pfizer Requester Portal.